Tasonermin

證據等級: L5

預測適應症: 10 個

Tasonermin: From Unconfirmed Original Indication to Prostatic Urethra Urothelial Carcinoma

One-Sentence Summary

Tasonermin is a recombinant TNF-alpha biologic; its original approved indication is not specified in the current data (DrugBank-only input, no TFDA/German license record). The TxGNN model predicts it may be effective for Prostatic Urethra Urothelial Carcinoma, but currently 0 clinical trials and 0 publications support this direction — the prediction is model-generated only.

Quick Overview

Item	Content
Original Indication	Not available (no license/regulatory record; drug is not marketed)
Predicted New Indication	Prostatic Urethra Urothelial Carcinoma
TxGNN Prediction Score	99.81%
Evidence Level	L5
Germany Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for Tasonermin. Based on the information present in this evidence pack, Tasonermin is a recombinant TNF-alpha (tumor necrosis factor-alpha) biologic. Mechanistically, TNF-alpha can induce tumor vascular endothelial damage, promote tumor necrosis, and drive immune cell infiltration — a broad-spectrum antitumor mechanism that, in theory, could apply across multiple solid tumor types.

However, no original indication is recorded in this pack, so the relationship between the drug's established use and the predicted new indication (prostatic urethra urothelial carcinoma) cannot be assessed. The mechanistic rationale provided is generic to TNF-alpha biology rather than specific to urothelial carcinoma pathophysiology.

Critically, there is no clinical trial or literature evidence — direct or indirect — linking Tasonermin to urothelial carcinoma. The connection is a pure TxGNN network-based prediction (evidence level L5), and the same caveat applies to all nine other predicted indications in this pack (renal pelvis carcinomas, HER2+ breast carcinoma, and several rare gynecological adenocarcinomas), none of which have supporting trials or publications.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

Cytotoxicity

Item	Content
Cytotoxicity Classification	Immunotherapy / biologic (cytokine-based, recombinant TNF-alpha) — not a conventional cytotoxic chemotherapeutic
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Please refer to the package insert for safety information.

Note: TFDA label warnings/contraindications are flagged as a Blocking data gap (DG001) in this evidence pack — this alone precludes any S1 safety pre-assessment regardless of predicted indication.

Conclusion and Next Steps

Decision: Hold

Rationale: The predicted indication is supported only by a TxGNN network score (L5, no clinical trials, no literature), and a Blocking-severity data gap exists for TFDA safety labeling — the combination means neither efficacy plausibility nor safety can currently be evaluated.

To proceed, the following is needed:

TFDA/EMA label data — warnings, contraindications, and precautions (DG001, Blocking)
Confirmed original indication(s) and full mechanism of action (DG002, High)
Disease-specific preclinical or clinical evidence connecting TNF-alpha biology to urothelial carcinoma (or any of the other 9 candidate indications)
Route of administration and formulation compatibility assessment (currently marked "pending" for all candidates)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.